

## CONTENTS

*List of Figures*

*List of tables*

*List of abbreviations*

*Preface*

---

| Chapters                                                          | Page No.  |
|-------------------------------------------------------------------|-----------|
| <b>1. Introduction.....</b>                                       | <b>1</b>  |
| 1.1 Introduction to lung cancer and its statistics .....          | 3         |
| 1.2 Types of lung cancer.....                                     | 4         |
| 1.3 Biology of lung cancer.....                                   | 4         |
| 1.4 Genetic basis of lung cancer.....                             | 5         |
| 1.5 Risk factors associated with lung cancer.....                 | 7         |
| 1.6 Diagnosis and screening of the lung cancer.....               | 8         |
| 1.7 Research gaps, hypothesis and rationale of the study.....     | 9         |
| <b>2. Literature Review.....</b>                                  | <b>15</b> |
| 2.1 Nasal route of drug administration.....                       | 17        |
| 2.1.1 Nasal anatomy.....                                          | 17        |
| 2.1.2 Olfactory region.....                                       | 18        |
| 2.1.3 Intranasal Drug Delivery Systems Against Cancer.....        | 19        |
| 2.2 Prior research art on lung cancer.....                        | 22        |
| 2.3 Gemcitabine (GEM).....                                        | 29        |
| 2.3.1 Mechanism of action of gemcitabine as anticancer agent..... | 29        |
| 2.3.2 Pharmacokinetics and metabolism of gemcitabine.....         | 30        |
| 2.3.3 Prior research art on gemcitabine.....                      | 30        |
| 2.4 Epigallocatechin-3-gallate (EGCG).....                        | 36        |
| 2.4.1 Mechanism of action of EGCG as anticancer agent.....        | 36        |
| 2.4.2 Prior research art on EGCG.....                             | 37        |
| 2.5 Excipients profile.....                                       | 43        |
| 2.5.1 Glyceryl Monostearate .....                                 | 43        |
| 2.5.2 Polyvinyl Alcohol .....                                     | 44        |
| 2.5.3 Pluronic F-127 .....                                        | 46        |
| 2.5.4 Hydrogenated soy phosphatidylcholine .....                  | 48        |

---

|                                                                                            |           |
|--------------------------------------------------------------------------------------------|-----------|
| 2.6 Solid Lipid Nanoparticles (SLNs).....                                                  | 49        |
| 2.6.1 Methods of preparation of SLNs.....                                                  | 50        |
| <b>3. Aim and Objectives.....</b>                                                          | <b>53</b> |
| 3.1 Aim.....                                                                               | 55        |
| 3.2 Objectives.....                                                                        | 55        |
| <b>4. Materials &amp; Methods.....</b>                                                     | <b>57</b> |
| 4.1 Materials.....                                                                         | 59        |
| 4.2 Methods.....                                                                           | 59        |
| 4.2.1 HPLC analytical method development and validation in PBS (pH 5.5) and<br>plasma..... | 59        |
| 4.2.2 Quality by design (QbD) based optimization of solid lipid<br>nanoparticles.....      | 60        |
| 4.2.3 Preparation of solid lipid nanoparticles.....                                        | 62        |
| 4.2.4 Characterization.....                                                                | 63        |
| 4.2.4.1 Micromeritics, zeta potential, and surface morphology analysis.....                | 63        |
| 4.2.4.2 Estimation of percent entrapment efficiency.....                                   | 64        |
| 4.2.4.3 Incompatibility study using Attenuated Total Reflectance (ATR).....                | 65        |
| 4.2.4.4 Thermogravimetric studies.....                                                     | 65        |
| 4.2.4.5 Differential scanning calorimetry studies.....                                     | 65        |
| 4.2.4.6 In vitro release studies and kinetic models.....                                   | 65        |
| 4.2.5 In vitro cell line studies.....                                                      | 68        |
| 4.2.5.1 Cytotoxicity assay.....                                                            | 68        |
| 4.2.5.2 Wound healing (scratch) assay.....                                                 | 70        |
| 4.2.5.3 Cellular uptake studies.....                                                       | 70        |
| 4.2.5.4 Annexin V/FITC apoptosis assay.....                                                | 71        |
| 4.2.5.5 Reactive oxygen species (ROS) assay.....                                           | 72        |
| 4.2.6 Stability studies.....                                                               | 72        |
| 4.2.7 Animal studies.....                                                                  | 72        |
| 4.2.8 Development of lung cancer animal model.....                                         | 73        |
| 4.2.9 Experimental study design.....                                                       | 74        |
| 4.2.10 Pharmacokinetic study.....                                                          | 75        |
| 4.2.10.1 Plasma pharmacokinetics.....                                                      | 75        |

|            |                                                                                           |           |
|------------|-------------------------------------------------------------------------------------------|-----------|
| 4.2.10.2   | <i>Lung pharmacokinetics</i> .....                                                        | 76        |
| 4.2.11     | <i>Lung targeting efficiency of the intranasal route</i> .....                            | 76        |
| 4.2.11.1.1 | <i>Drug Targeting Index</i> .....                                                         | 76        |
| 4.2.11.1.2 | <i>IVIS- In vivo imaging system</i> .....                                                 | 77        |
| 4.2.12     | <i>Biodistribution study</i> .....                                                        | 77        |
| 4.2.13     | <i>Histopathological study</i> .....                                                      | 78        |
| 4.2.14     | <i>Assessment of safety and biocompatibility of SLNs</i> .....                            | 78        |
| 4.2.14.1.1 | <i>Safety assessment of SLNs in the main metabolizing organs</i> .....                    | 78        |
| 4.2.14.1.2 | <i>Safety assessment of SLNs in the blood-Hemolysis study</i> .....                       | 79        |
| 4.2.14.1.3 | <i>Safety assessment of GEM-EGCG SLNs in the nasal region of Swiss albino mice</i> .....  | 80        |
| 4.2.15     | <i>Statistical analysis</i> .....                                                         | 80        |
| <b>5.</b>  | <b>Results &amp; Discussion</b> .....                                                     | <b>81</b> |
| 5.1        | <i>HPLC analytical method development and validation in PBS (pH 5.5) and plasma</i> ..... | 83        |
| 5.2        | <i>Optimization studies</i> .....                                                         | 87        |
| 5.3        | <i>Characterization of SLNs</i> .....                                                     | 96        |
| 5.3.1      | <i>Micromeritics, and zeta potential</i> .....                                            | 96        |
| 5.3.2      | <i>Surface morphology analysis</i> .....                                                  | 99        |
| 5.3.3      | <i>Percent entrapment efficiency</i> .....                                                | 100       |
| 5.3.4      | <i>Incompatibility study using Attenuated Total Reflectance (ATR)</i> .....               | 100       |
| 5.3.5      | <i>Thermogravimetric analysis</i> .....                                                   | 102       |
| 5.3.6      | <i>Differential scanning calorimetry (DSC) analysis</i> .....                             | 103       |
| 5.3.7      | <i>In vitro release studies and kinetic models</i> .....                                  | 105       |
| 5.4        | <i>In vitro cell line studies</i> .....                                                   | 109       |
| 5.4.1      | <i>Cytotoxicity assay</i> .....                                                           | 109       |
| 5.4.2      | <i>Wound healing (scratch) assay</i> .....                                                | 110       |
| 5.4.3      | <i>Cellular uptake studies</i> .....                                                      | 112       |
| 5.4.4      | <i>Annexin V/FITC apoptosis assay</i> .....                                               | 114       |
| 5.4.5      | <i>Reactive oxygen species (ROS) assay</i> .....                                          | 115       |
| 5.5        | <i>Stability studies</i> .....                                                            | 117       |
| 5.6        | <i>Pharmacokinetic study</i> .....                                                        | 118       |

|           |                                                                                          |            |
|-----------|------------------------------------------------------------------------------------------|------------|
| 5.6.1     | <i>Pharmacokinetics (Lung &amp;Plasma)</i> .....                                         | 118        |
| 5.7       | <i>Lung targeting efficiency of intranasal route</i> .....                               | 124        |
| 5.7.1     | <i>Drug Targeting Index</i> .....                                                        | 124        |
| 5.7.2     | <i>IVIS-In vivo imaging system</i> .....                                                 | 125        |
| 5.8       | <i>Biodistribution study</i> .....                                                       | 128        |
| 5.9       | <i>Histopathological study</i> .....                                                     | 130        |
| 5.10      | <i>Assessment of safety and biocompatibility of SLNs</i> .....                           | 133        |
| 5.10.1    | <i>Safety assessment of SLNs in the major metabolizing organs</i> .....                  | 133        |
| 5.10.2    | <i>Safety assessment of SLNs in the blood-Hemolysis study</i> .....                      | 134        |
| 5.10.3    | <i>Safety assessment of GEM-EGCG SLNs in the nasal region of Swiss albino mice</i> ..... | 136        |
| <b>6.</b> | <b>Summary, limitations and future perspectives</b> .....                                | <b>139</b> |
| 6.1       | Summary.....                                                                             | 141        |
| 6.2       | Limitations.....                                                                         | 144        |
| 6.3       | Future perspectives.....                                                                 | 145        |
| <b>7.</b> | <b>Conclusion</b> .....                                                                  | <b>147</b> |
| <b>8.</b> | <b>References</b> .....                                                                  | <b>151</b> |
| <b>9.</b> | <b>Publications</b> .....                                                                | <b>185</b> |